Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics reports that stockholders approved a set of proposals that enables a change in control, large potential share issuance and structural changes to its charter and bylaws.
Following a prior preferred stock investment by David E. Lazar, stockholders approved issuing common shares upon conversion of 300,000 Series AA and 700,000 Series AAA Convertible Preferred Stock. After the related charter amendment filing, these preferred shares are convertible at Mr. Lazar’s option into 111.0 million common shares, representing about 96.4% of common stock on a fully diluted basis.
Stockholders also authorized the board to implement up to two reverse stock splits in a 1‑for‑2 to 1‑for‑199 range, approved increasing authorized common shares to 1,000,000,000 and allowed stockholder action by written consent. Two directors, Jerome Jabbour and Matthew McMurdo, were elected, giving Mr. Lazar’s nominees a majority of the nine‑member board.
Indaptus Therapeutics, Inc. filed an initial insider ownership report for board member Jerome D. Jabbour on Form 3. This filing establishes his status as a director subject to insider reporting rules. The report does not list any buy, sell, or other share transactions.
Indaptus Therapeutics, Inc. director Matthew Charles McMurdo reported his initial ownership of the company’s common stock. He holds 25,000 shares of common stock directly, as shown in this initial statement of beneficial ownership.
Indaptus Therapeutics Co-Chief Executive Officer and director Jeffrey Meckler reported derivative warrant transactions tied to a board-approved repricing. On February 11, 2026, previously held warrants were disposed of back to the company and replacement warrants were acquired on a direct ownership basis.
The transactions cover several warrant series exercisable for common stock, with the board unilaterally reducing the per-share exercise price of all affected warrants to $1.75 while leaving all other terms unchanged. Following the dispositions and matching acquisitions, Meckler directly holds new warrants for 3,033, 1,519, and 12,136 underlying shares at the revised exercise price.
The filing also notes that on June 26, 2025, Indaptus implemented a 1-for-28 reverse stock split of its common stock, and all warrant amounts in the report reflect this adjustment.
Indaptus Therapeutics entered into warrant repricing agreements with certain holders of warrants to purchase an aggregate 913,638 shares of common stock that were originally issued in 2024 and 2025 at exercise prices ranging from $8.30 to $47.60. The company reduced the exercise price of these warrants to $1.75 per share, which matches the Nasdaq-defined “Minimum Price.” In return, these holders agreed under a voting agreement to vote all their common shares in favor of all proposals at a special stockholder meeting scheduled for February 26, 2026. The board also unilaterally reduced the exercise price to $1.75 for additional warrants and placement agent warrants to purchase an aggregate 762,787 shares from the same financing rounds, leaving all other warrant terms unchanged.
Indaptus Therapeutics director Avraham Ben-Tzvi reported new equity awards. On January 20, 2026, he received 25,000 shares of restricted common stock as compensation under a consulting agreement, and these shares vested in full immediately upon grant. Following this award, he beneficially owns 25,100 shares of Indaptus common stock, including 100 shares held in a Roth IRA.
Separately, on December 23, 2025, he was granted options to purchase 25,000 shares of Indaptus common stock under the company’s non-employee director compensation program. These stock options vest over three years in equal quarterly installments, so long as he continues to serve on the board through each vesting date.
Indaptus Therapeutics director David Natan received a new stock option grant covering 25,000 shares of common stock. The options have an exercise price of $2.69 per share and were granted on January 7, 2026 under the company’s non-employee director compensation program. The award vests over three years in equal quarterly installments starting from the grant date, as long as Natan continues to serve on the board through each vesting date. Following this grant, he beneficially holds 25,000 stock options directly.
Indaptus Therapeutics has called a February 26, 2026 special meeting to ask stockholders to approve a transformative recapitalization built around a recent $6.0 million preferred stock investment by David E. Lazar. The company sold 300,000 Series AA and 700,000 Series AAA Convertible Preferred shares at $6.00 each; after stockholder approval these can convert into 111.0 million common shares. Based on 2,242,324 common shares outstanding as of January 21, 2026, full conversion would give the new investor about 96.4% of the fully diluted common, sharply diluting existing holders and concentrating voting power. Proposals also include electing two Lazar nominees to the board, authorizing a reverse stock split in a 1‑for‑2 to 1‑for‑199 range, increasing authorized common from 200,000,000 up to 1,000,000,000 shares, permitting stockholder action by written consent, and related Nasdaq change of control and issuance approvals.
Indaptus Therapeutics, Inc. reported changes to executive compensation and board composition. The company entered into salary adjustment agreements with Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman, Ph.D. Effective January 15, 2026, each executive’s salary was set at $60,000 per year for the remainder of the year, paid according to the company’s standard payroll practices.
The company also disclosed that board member Anthony Maddaluna, who had previously notified the company of his intention to resign as of the next special meeting of stockholders, has rescinded that resignation. He will remain on the Board of Directors and continue to serve on the Compensation Committee and Nominating Committee.
Indaptus Therapeutics, Inc. director David Natan filed an initial ownership report stating that he currently holds no shares of the company. The filing shows that he has no beneficial ownership of non-derivative or derivative securities of Indaptus as of the event date, and his position is reported as a director filing on his own behalf.